Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
about
Diuretics: a review and updateMortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.Control of Blood Pressure and Risk Attenuation: Post Trial Follow-Up of Randomized Groups.Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT])Hyponatremia is Associated with Fluid Imbalance and Adverse Renal Outcome in Chronic Kidney Disease Patients Treated with Diuretics.Hypertension in black patients: an update.Pharmacotherapy for hypertension in older adults: a systematic review.Long-term survival following the development of heart failure in an elderly hypertensive population.Effect of Race and Ethnicity on Antihypertensive Medication Utilization Among Women in the United States: Study of Women's Health Across the Nation (SWAN).Strategies to improve control of blood pressure in hypertension: moving towards a 70% objective.The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications.Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
P2860
Q28302157-E2804EBC-C0B4-4CDB-9E21-C68CF9A7E2DCQ33965660-64017100-C18F-4320-A8F6-3D8E287699E3Q34546377-5AC03AB5-3052-45F1-9118-6182B2A16282Q34625364-7BEE0C4B-4AF1-4EBB-BC86-5713CE4F85A9Q35833486-2BA4CC35-9178-4B76-A78B-5234D660DD05Q36025075-42EF1891-8E2B-47A3-97D9-52C55088D8C4Q36403208-6670A3F6-7AE6-4FFD-82E2-FBE45277201AQ37412041-EF4D3217-7B2B-4125-A20A-719E7C454A36Q38113096-2D16DA2B-87E0-4C78-86B7-E545F4719617Q38260843-AE645102-579B-4D91-9E9E-893F296ABF43Q38599662-60FC336C-EC78-4695-AC4E-689C117A2FFBQ40321256-E2640069-7F7C-4D8A-9782-1620326289FCQ46203356-D803D55A-E85F-4343-9F00-9777632F7681Q47648986-54ABB867-5A97-4BF7-A216-EE574631BABCQ47747042-9C41BE8E-AC63-45EA-A2E0-606719FE44C1
P2860
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Mortality and morbidity during ...... to Prevent Heart Attack Trial
@ast
Mortality and morbidity during ...... to Prevent Heart Attack Trial
@en
type
label
Mortality and morbidity during ...... to Prevent Heart Attack Trial
@ast
Mortality and morbidity during ...... to Prevent Heart Attack Trial
@en
prefLabel
Mortality and morbidity during ...... to Prevent Heart Attack Trial
@ast
Mortality and morbidity during ...... to Prevent Heart Attack Trial
@en
P2093
P2860
P1476
Mortality and morbidity during ...... to Prevent Heart Attack Trial
@en
P2093
ALLHAT Collaborative Research Group
Barry R Davis
Bruce P Hamilton
Carol Stanford
Charles E Ford
Henry R Black
Jackson T Wright
Jan N Basile
Jeffrey A Cutler
Jeffrey L Probstfield
P2860
P356
10.1111/J.1751-7176.2011.00568.X
P577
2011-12-09T00:00:00Z